News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pfizer Inc. (PFE)'s Back-Pain Medication Meets Primary Phase 3 Goals



1/23/2014 8:21:22 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Pfizer Inc. (PFE: Quote) reported top-line results of Phase 3 trial of investigational agent ALO-02 in patients with moderate-to-severe chronic low back pain. During this study, ALO-02 met the primary efficacy endpoint, showing a statistically significant difference from placebo.

Help employers find you! Check out all the jobs and post your resume.

Read at RTT News
Read at Wall Street Journal
Read at News Release


comments powered by Disqus
   
Back Pain

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES